UK ad authority on J&J ad
This article was originally published in The Rose Sheet
Executive SummaryA print advertisement for Johnson & Johnson's RoC CompleteLift Face Cream in the UK must not appear again in its current form, according to the UK's Advertising Standards Authority, an independent organization created by the UK advertising industry to monitor ads. ASA reviewed the ad following two complaints regarding claims, including "Measurable lift in just 8 weeks," "clinically proven to work in just 8 weeks of use," "clinically proven to work" and one that the product contains a patented ingredient that "retightens and firms the facial contours by contracting skin cells." J&J defended its claims, stating they were substantiated by a clinical study confirmed by consumer perception data. However, ASA concluded the evidence from the clinical study did not support the efficacy of the product, so the claims are misleading to consumers
You may also be interested in...
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.
In 2019, Mylan moved up to become the world’s leading generics, biosimilars and OTC player, according to Informa Pharma Intelligence’s latest global rankings. Sandoz has surpassed troubled Teva into second place but is set to surrender that position following the sale of its US solid-dose and dermatology business to India’s Aurobindo.